Short- and Long-Term Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination in Patients with Multiple Sclerosis Treated with Disease-Modifying Therapies.
Sainz de la Maza S, Walo-Delgado PE, Rodríguez-Domínguez M, Monreal E, Rodero-Romero A, Chico-García JL, Pariente R, Rodríguez-Jorge F, Ballester-González R, Villarrubia N, Romero-Hernández B, Masjuan J, Costa-Frossard L, Villar LM.
Sainz de la Maza S, et al. Among authors: romero hernandez b.
Vaccines (Basel). 2023 Apr 3;11(4):786. doi: 10.3390/vaccines11040786.
Vaccines (Basel). 2023.
PMID: 37112698
Free PMC article.